Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**4-[3-(4-chlorophenyl)-2,1-benzisoxazol–5–yl]pyrimidin–2–amine** is a synthetic small molecule that acts as an experimental inhibitor of serine/threonine-protein kinase pim‑1 (PIM‑1). It belongs to the class of aminopyrimidines and derivatives. The compound has been studied for its ability to inhibit PIM‑1 kinase activity with a reported Ki of approximately 91 nM. PIM‑1 is implicated in cell survival and proliferation pathways and is considered a potential target in oncology research. This compound has not been approved for clinical use and remains at the experimental stage[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-[3-(4-chlorophenyl)-2,1-benzisoxazol-5-yl]pyrimidin-2-amine.